Synergistic anti-osteosarcoma cell effects of the methotrex-ate/PI3K/mTOR inhibitor nanoparticle codelivery system

References

• Shabib Akhtar M, Chandrasekaran K, Saminathan S, et al. Nanoengineered chitosan functionalized titanium dioxide biohybrids for bacterial infections and cancer therapy. Sci Rep. 2024;14(1):3705. doi: 10.1038/s41598-024-52847-1
   PubMed Web of Science ®Google Scholar
• Chen C, Xie L, Ren T, et al. Immunotherapy for osteosarcoma: fundamental mechanism, rationale, and recent breakthroughs. Cancer Lett. 2021;500:1–14. doi: 10.1016/j.canlet.2020.12.024
   PubMed Web of Science ®Google Scholar
• Kozminski P, Halik PK, Chesori R, et al. Overview of dual-acting drug methotrexate in different neurological diseases, autoimmune pathologies and cancers. Int J Mol Sci. 2020;21(10):3483. doi: 10.3390/ijms21103483
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhang Q, Zheng TT, et al. Delayed high-dose methotrexate excretion and influencing factors in osteosarcoma patients. Chin Med J (Engl). 2016;129(21):2530–2534. doi: 10.4103/0366-6999.192781
   PubMed Web of Science ®Google Scholar
• Tian Z, Guo B, Yu M, et al. Upregulation of micro-ribonucleic acid-128 cooperating with downregulation of PTEN confers metastatic potential and unfavorable prognosis in patients with primary osteosarcoma. Onco Targets Ther. 2014;7:1601–1608. doi: 10.2147/OTT.S67217
   PubMed Web of Science ®Google Scholar
• Zheng C, Tang F, Min L, et al. PTEN in osteosarcoma: recent advances and the therapeutic potential. Biochim Biophys Acta Rev Cancer. 2020;1874(2):188405. doi: 10.1016/j.bbcan.2020.188405
   PubMed Web of Science ®Google Scholar
• Tonlaar N, Galoforo S, Thibodeau BJ, et al. Antitumor activity of the dual PI3K/MTOR inhibitor, PF-04691502, in combination with radiation in head and neck cancer. Radiother Oncol. 2017;124(3):504–512. doi: 10.1016/j.radonc.2017.08.001
   PubMed Web of Science ®Google Scholar
• Wang J, Yue H, Huang X, et al. Novel nano-platinum induces autophagy through dual pathways in the treatment of osteosarcoma in cell lines with different P53 expression patterns. Chem Eng J. 2024;488:151071. doi: 10.1016/j.cej.2024.151071
   Web of Science ®Google Scholar
• Shang X, Na X, Wang L, et al. Evaluation of a dual PI3K/mTOR inhibitor PF-04691502 against bladder cancer cells. Evid Based Complement Alternat Med. 2022;2022:1–10. doi: 10.1155/2022/8110796
   Web of Science ®Google Scholar
• Yuan J, Mehta PP, Yin MJ, et al. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol Cancer Ther. 2011;10(11):2189–2199. doi: 10.1158/1535-7163.MCT-11-0185
   PubMed Web of Science ®Google Scholar
• Cersosimo F, Lonardi S, Bernardini G, et al. Tumor-associated macrophages in osteosarcoma: from mechanisms to therapy. Int J Mol Sci. 2020;21(15):5207. doi: 10.3390/ijms21155207
   PubMed Web of Science ®Google Scholar
• Marina NM, Smeland S, Bielack SS, et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016;17(10):1396–1408. doi: 10.1016/S1470-2045(16)30214-5
   PubMed Web of Science ®Google Scholar
• Smrke A, Anderson PM, Gulia A, et al. Future directions in the treatment of osteosarcoma. Cells. 2021;10(1):172. doi: 10.3390/cells10010172
   PubMed Web of Science ®Google Scholar
• Ashique S, Faiyazuddin M, Afzal O, et al. Advanced nanoparticles, the hallmark of targeted drug delivery for osteosarcoma-an updated review. J Drug Delivery Sci Technol. 2023;87:104753. doi: 10.1016/j.jddst.2023.104753
   Web of Science ®Google Scholar
• Haritha V, Gowri S, Janarthanan B, et al. Biogenic synthesis of nickel oxide nanoparticles using averrhoa bilimbi and investigation of its antibacterial, antidiabetic and cytotoxic properties. Inorg Chem Commun. 2022;144:109930. doi: 10.1016/j.inoche.2022.109930
   Web of Science ®Google Scholar
• Chen D, Liu X, Lu X, et al. Nanoparticle drug delivery systems for synergistic delivery of tumor therapy. Front Pharmacol. 2023;14:1111991. doi: 10.3389/fphar.2023.1111991
   PubMed Web of Science ®Google Scholar
• Shi Y, van der Meel R, Chen X, et al. The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy. Theranostics. 2020;10(17):7921–7924. doi: 10.7150/thno.49577
   PubMed Web of Science ®Google Scholar
• Zhu G, Wang B, Feng G, et al. A nano-preparation approach to enable the delivery of daphnoretin to potentiate the therapeutical efficacy in hepatocellular cancer. Front Pharmacol. 2022;13:965131. doi: 10.3389/fphar.2022.965131
   PubMed Web of Science ®Google Scholar
• Sun Q, Liang J, Lin Y, et al. Preparation of nano-sized multi-vesicular vesicles (MVVs) and its application in co-delivery of doxorubicin and curcumin. Colloids Surf B Biointerfaces. 2023;229:113471. doi: 10.1016/j.colsurfb.2023.113471
   PubMed Web of Science ®Google Scholar
• Chen W, Liu X, Li Y, et al. Preparation and in vitro evaluation of a nano ultrasound contrast agent targeting pancreatic cancer. J Nanosci Nanotechnol. 2021;21(3):1413–1418. doi: 10.1166/jnn.2021.18883
   PubMedGoogle Scholar
• Li Y, Liu Y, Yao B, et al. Rapid preparation and antimicrobial activity of polyurea coatings with RE-Doped nano-ZnO. Microbiol Biotechnol. 2022;15(2):548–560. doi: 10.1111/1751-7915.13891
   Google Scholar
• Wang A, Cui J, Wang Y, et al. Preparation and characterization of a novel controlled-release nano-delivery system loaded with pyraclostrobin via high-pressure homogenization. Pest Manag Sci. 2020;76(8):2829–2837. doi: 10.1002/ps.5833
   PubMed Web of Science ®Google Scholar
• Barbhuiya RI, Singha P, Asaithambi N, et al. Ultrasound-assisted rapid biological synthesis and characterization of silver nanoparticles using pomelo peel waste. Food Chem. 2022;385:132602. doi: 10.1016/j.foodchem.2022.132602
   PubMed Web of Science ®Google Scholar
• Amiryaghoubi N, Abdolahinia ED, Nakhlband A, et al. Smart chitosan-folate hybrid magnetic nanoparticles for targeted delivery of doxorubicin to osteosarcoma cells. Colloids Surf B Biointerfaces. 2022;220:112911. doi: 10.1016/j.colsurfb.2022.112911
   PubMed Web of Science ®Google Scholar
• Wang L, Huang X, You X, et al. Nanoparticle enhanced combination therapy for stem-like progenitors defined by single-cell transcriptomics in chemotherapy-resistant osteosarcoma. Signal Transduct Target Ther. 2020;5(1):196. doi: 10.1038/s41392-020-00248-x
   PubMed Web of Science ®Google Scholar
• Liu H, Zhang R, Zhang D, et al. Cyclic RGD-decorated liposomal gossypol AT-101 targeting for enhanced antitumor effect. Int J Nanomedicine. 2022;17:227–244. doi: 10.2147/IJN.S341824
   PubMed Web of Science ®Google Scholar
• Wong PT, Choi SK. Mechanisms and implications of dual-acting methotrexate in folate-targeted nanotherapeutic delivery. Int J Mol Sci. 2015;16(1):1772–1790. doi: 10.3390/ijms16011772
   PubMed Web of Science ®Google Scholar
• Ko S, Park J, Lee Y, et al. Biochemical reprogramming of tumors for active modulation of receptor-mediated nanomaterial delivery. Biomaterials. 2020;262:120343. doi: 10.1016/j.biomaterials.2020.120343
   PubMed Web of Science ®Google Scholar
• Wang C, Wang B, Zou S, et al. Cyclo-gamma-polyglutamic acid-coated dual-responsive nanomicelles loaded with doxorubicin for synergistic chemo-photodynamic therapy. Biomater Sci. 2021;9(17):5977–5987. doi: 10.1039/D1BM00713K
   PubMed Web of Science ®Google Scholar
• Lilienthal I, Herold N. Targeting molecular mechanisms underlying treatment efficacy and resistance in osteosarcoma: a review of current and future strategies. Int J Mol Sci. 2020;21(18):6885. doi: 10.3390/ijms21186885
   PubMed Web of Science ®Google Scholar
• Bertacchini J, Heidari N, Mediani L, et al. Targeting PI3K/AKT/mTOR network for treatment of leukemia. Cell Mol Life Sci. 2015;72(12):2337–2347. doi: 10.1007/s00018-015-1867-5
   PubMed Web of Science ®Google Scholar
• Shijie L, Zhen P, Kang Q, et al. Deregulation of CLTC interacts with TFG, facilitating osteosarcoma via the TGF-beta and AKT/mTOR signaling pathways. Clin Transl Med. 2021;11(6):e377. doi: 10.1002/ctm2.377
   PubMed Web of Science ®Google Scholar
• Gupte A, Baker EK, Wan SS, et al. Systematic screening identifies dual PI3K and mTOR inhibition as a conserved therapeutic vulnerability in osteosarcoma. Clin Cancer Res. 2015;21(14):3216–3229. doi: 10.1158/1078-0432.CCR-14-3026
   PubMed Web of Science ®Google Scholar
• Plana D, Palmer AC, Sorger PK. Independent drug action in combination therapy: implications for precision oncology. Cancer Discov. 2022;12(3):606–624. doi: 10.1158/2159-8290.CD-21-0212
   PubMed Web of Science ®Google Scholar
• Patra JK, Das G, Fraceto LF, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol. 2018;16(1):71. doi: 10.1186/s12951-018-0392-8
   PubMed Web of Science ®Google Scholar
• Machtakova M, Therien-Aubin H, Landfester K. Polymer nano-systems for the encapsulation and delivery of active biomacromolecular therapeutic agents. Chem Soc Rev. 2022;51(1):128–152. doi: 10.1039/D1CS00686J
   PubMed Web of Science ®Google Scholar